By the Top Tier Newswire AI Desk · October 13, 2026 at 3:34 PM ET · reviewed against 3 wire stories
ABSCI CORP (ABSI) is down -6.93% in the latest session. Our newswire has captured 3 stories on ABSI across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ABSI stock fell 6.93% to $9.00 on Tuesday. The decline followed the company’s announcement that it will report third-quarter 2026 financial and operating results before market open on November 12. The move occurred despite a recent price target increase from JPMorgan.
What Happened
Absci Corporation, a clinical-stage biopharmaceutical company advancing therapeutics designed with generative AI, announced it will release its Q3 2026 results on November 12. The company scheduled an 8:00 a.m. ET webcast to discuss business developments and outlook. The announcement highlighted the firm’s generative AI drug-creation platform.
In the same period, JPMorgan raised its price target for ABSI to $15 from $14. Other analysts also maintained positive stances, with HC Wainwright & Co. reiterating a Buy rating with a $16 price target and Needham reiterating a Buy rating with an $11 price target. Despite these ratings, the stock traded lower in the session.
What The Data Shows
The stock opened at $9.75, a 0.8% gap up from the prior close of $9.67. It reached a session high of $9.78 at 7:05 a.m. ET before sliding to a session low of $9.00 at 3:30 p.m. ET. Volume stood at 1.7 million shares, which is 0.4 times the three-month daily average.
Fundamentals show a market cap of $1.7 billion. The company is unprofitable with a trailing twelve-month EPS of -0.80 and revenue down 62.3% over the same period. The stock has a beta of 2.28. Over the last 52 weeks, the price range is $2.24 to $12.05. In the last eight sessions, the stock moved down 13.9% from $11.23 to $9.67. On October 13, 2026, the stock printed six fresh 52-week highs and 13 fresh 52-week lows.
What To Watch
Investors will focus on the November 12 earnings release and the accompanying webcast. The upcoming report will provide details on the company’s generative AI platform and future outlook.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ABSI · today's session (5-min) · -5.57% vs prior close · updated 5:55 PM ETAI sentiment, last 36h · averaged over 3 stories · 55/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
11h agoMarketChameleonNEUTRAL 53Product/PR
Absci Sets November 12 Call for Q3 2026 Results, Spotlighting Its Generative AI Drug-Creation Platform
October 13, 2026
Absci (NASDAQ: ABSI) said it will report Q3 2026 financial and operating results before market open on November 12, 2026, followed by an 8:00 a.m. ET webcast to discuss business developments and outlook. The company highlighted its generative AI-driven Integrated Drug Creation platform and referenced internal pipeline work including ABS-201 for hair regrowth and investigation in endometriosis.
12h agoBusiness InsiderNEUTRAL 50Earnings
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the...
1d agoThe FlyBULLISH 63Analyst
Absci price target raised to $15 from $14 at JPMorgan
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →